Premier Biotech Expands Globally With NexScreen and TransMed Acquisitions
Event summary
- Premier Biotech acquired NexScreen and TransMed in June 2026, expanding its global footprint and product portfolio.
- NexScreen provides point-of-care diagnostic testing solutions in the U.S., Australia, and New Zealand.
- TransMed offers a broad catalog of drug testing products and laboratory supplies with a strong e-commerce platform.
- Premier Biotech has completed seven acquisitions since partnering with Align Capital Partners in November 2022.
The big picture
Premier Biotech's acquisitions of NexScreen and TransMed align with its strategy to expand globally and enhance its product offerings. The move comes as the diagnostic testing market continues to evolve, with increasing demand for comprehensive, end-to-end solutions. Align Capital Partners' involvement underscores the private equity firm's focus on growth-oriented investments in the biotech sector.
What we're watching
- Integration Challenges
- How Premier Biotech will integrate NexScreen and TransMed's operations and customer bases into its existing structure.
- Market Penetration
- Whether the acquisitions will significantly boost Premier Biotech's presence in Australia and New Zealand.
- Future Acquisitions
- The pace at which Premier Biotech will pursue additional acquisition opportunities to accelerate growth.
Related topics